Smartphone Device Created Performs Blood Tests
|
By LabMedica International staff writers Posted on 03 Apr 2014 |

Image: Schematics of the Qloudlab smartphone device (Photo courtesy of Alain Herzog).
A smartphone device has been created that can perform blood tests—an innovation that could improve the quality of life for people undergoing treatment for the prevention of blood clots.
The formation of blood clots in the arteries and veins can increase the risk of heart attack and stroke, and individuals at high risk of blood clots are often treated with anticoagulants drugs that thin the blood and prevent the clotting process.
Bioengineers at the École Polytechnique Fédérale de Lausanne (EPFL; Switzerland) microengineering laboratory have created a device that could allow patients undergoing anticoagulant therapy to self-monitor. The gadget consists of a small single-use film that is attached to the screen of a smartphone. The film is made of a microstructured plastic layer that is a few micrometers thick.
When blood enters the film through capillary action, the device can detect a molecule present in blood that initiates coagulation, the process by which blood forms clots. The phone is then able to interpret the results by analyzing interferences in the electric field on the surface of the smartphone's screen. This is a process similar to what happens when a finger comes into contact with the screen of a smartphone. The results are then sent to a specific smartphone application, created by Qloudlab (Lausanne, Switzerland), the start-up company based at EPFL. This data can then be sent directly to a physician, who can assess whether a patient’s treatment needs to be modified.
Qloudlab has recently applied for a patent for the device, and the creators have recently received funding from Venture Kick (St. Gallen, Switzerland) that has allowed them to recruit a biochemist. The team hopes that by the end of next year, they will have shown that the device is as reliable as a laboratory test and can progress toward commercialization. Arther Queval, MSc, the founder of Qloudlab, said, “Such a test will significantly improve the quality of life for people undergoing this kind of treatment."
Related Links:
École Polytechnique Fédérale de Lausanne
Qloudlab
Venture Kick
The formation of blood clots in the arteries and veins can increase the risk of heart attack and stroke, and individuals at high risk of blood clots are often treated with anticoagulants drugs that thin the blood and prevent the clotting process.
Bioengineers at the École Polytechnique Fédérale de Lausanne (EPFL; Switzerland) microengineering laboratory have created a device that could allow patients undergoing anticoagulant therapy to self-monitor. The gadget consists of a small single-use film that is attached to the screen of a smartphone. The film is made of a microstructured plastic layer that is a few micrometers thick.
When blood enters the film through capillary action, the device can detect a molecule present in blood that initiates coagulation, the process by which blood forms clots. The phone is then able to interpret the results by analyzing interferences in the electric field on the surface of the smartphone's screen. This is a process similar to what happens when a finger comes into contact with the screen of a smartphone. The results are then sent to a specific smartphone application, created by Qloudlab (Lausanne, Switzerland), the start-up company based at EPFL. This data can then be sent directly to a physician, who can assess whether a patient’s treatment needs to be modified.
Qloudlab has recently applied for a patent for the device, and the creators have recently received funding from Venture Kick (St. Gallen, Switzerland) that has allowed them to recruit a biochemist. The team hopes that by the end of next year, they will have shown that the device is as reliable as a laboratory test and can progress toward commercialization. Arther Queval, MSc, the founder of Qloudlab, said, “Such a test will significantly improve the quality of life for people undergoing this kind of treatment."
Related Links:
École Polytechnique Fédérale de Lausanne
Qloudlab
Venture Kick
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







